Technical Analysis with a Quantitative Edge

SIGN UP  |  LOGIN

HOW IT WORKS    TRADE SIGNALS    SCREENER    MY PORTFOLIO    HELP

Merrimack Pharmaceuticals, Inc. (MACK)
Equity - Health Care - Major Pharmaceuticals

 

As of 2018-05-22

Add to My Portfolio
Close8.71Open8.69
Prev Close8.70Daily Chg+0.01 (+0.11%)
High8.79Volume51,161
Low8.6452-Week High/Low15.09 / 1.16
Dividend Yield0%Curr P/E0.37
Curr Year EPS Est33.49Fwd P/E0.35
P/B1.47Short Ratio18.07
P/S1.09PEG Ratio0.06
Latest QuantForecast
As Of
Customize QuantForecast   View Commentary & Pattern   Save To My Forecasts     Share

 
 
 

SUPPORT
20SMA: 8.66 Lower Boll Band: 8.30
RESISTANCE
9EMA: 8.72 50SMA: 8.74 Upper Boll Band: 9.01
COMMENTARY
Mixed to negative trend . Momentum is deteriorating with Slow Stochastics turning lower and Fast Stochastics turning lower. Near-term technicals are overbought with MACD above zero 31 Days in a row. Forecast points to higher price with conviction
TECHNICAL PATTERN

TYPEDESCRIPTION (?)CRITERIA (?)
Short-Term Positive Momentum Price Tested but Closed Above 20-Day Simple Moving Average Close Above 20DMA AND Low Below 20DMA
Short-Term Negative Momentum Price Tested but Closed Under 9-Day Exponential Moving Average Close Below 9EMA AND High Above 9EMA
Long-Term Up Trend 200-Day Simple Moving Average is Trending Higher 200SMA Trend > 0
FORECAST STATISTICS
TIMEFRAME 2-DAY 5-DAY 10-DAY 20-DAY
Average +1.99% +3.62% +1.56% +0.99%
Best +9.46% +22.11% +18.13% +22.49%
Worst -7.07% -11.39% -14.99% -29.55%
% Positive 71% 64% 57% 64%
Outlook BULLISH BULLISH NEUTRAL BULLISH
HISTORICAL MATCHES (?)
MATCH DATE 2-DAY 5-DAY 10-DAY 20-DAY
2018-05-22 0% 0% 0% 0%
2018-04-20 -0.35% +2.24% +2.83% +3.18%
2018-03-02 +4.00% +5.27% -6.00% -29.55%
2018-03-01 +4.50% +6.89% -6.62% -26.01%
2017-11-28 -3.18% -9.88% -14.99% -12.81%
2015-08-19 -7.07% -2.32% -1.74% +4.07%
2015-03-12 +4.72% +7.66% +0.27% +8.47%
2014-11-28 +1.86% +5.79% +16.16% +22.49%
2014-09-23 +9.46% +22.11% +11.68% +20.72%
2014-09-22 +2.23% +17.43% +18.13% +21.06%
2014-08-22 +2.28% +5.92% +4.25% +8.80%
# Matches 14 Next
TRADE SIGNALS ?
POSITIONENTRY DATEENTRY PRICETARGET PRICE (?)STOP PRICE (?)CURRENT PNL %
Premium Members Only

Upgrade Now & Subscribe to Daily Trade Signals

CLOSED TRADES
POSITIONENTRY DATEENTRY PRICEEXIT DATE EXIT PRICEREALIZED PNL %
Short 2016-03-21 8.30 2016-04-28 7.29 +12.17%
Long 2014-04-29 4.49 2014-05-08 6.38 +42.09%
Related Stocks
SYMBOL NAME Close VOLUME CHG WTD MTD YTD QUANTFORECAST(?)
2-DAY 5-DAY 10-DAY 20-DAY
JNJ Johnson & Johnson 122.92 4,606,534 -0.75 (-0.61%) -1.37 (-1.10%) -3.86 (-3.04%) +8.46 (+7.39%)
PFE Pfizer, Inc. 35.74 11,770,491 -0.05 (-0.15%) +0.09 (+0.24%) -0.88 (-2.42%) +3.89 (+12.21%)
MRK Merck & Company, Inc. 58.47 7,007,743 -0.10 (-0.17%) -0.66 (-1.12%) -0.43 (-0.73%) +0.03 (+0.05%)
SNY Sanofi 38.93 942,106 +0.14 (+0.36%) +0.06 (+0.15%) -0.38 (-0.97%) -1.51 (-3.73%)
ABBV AbbVie Inc. 106.29 7,633,383 +0.11 (+0.10%) +0.32 (+0.30%) +9.74 (+10.09%) +44.93 (+73.23%)
>>> See More Related Stocks
LATEST BUZZ
@DosGatos
Posted 2018-05-23T18:58:36Z
$MACK 5 weeks to go Peters!
@scistats
Posted 2018-05-23T13:19:29Z
$MACK Right-To-Try Intralipid + Onivyde/MM-310 anyone? Its about time! Thank you Carnegie Mellon University!
@scistats
Posted 2018-05-23T13:14:00Z
$MACK Merrimack management must address how Ipsen's Right-To-Try "PROFITS" for 1st line PC, SCLC & 1 other indication affect MACK's 450M.
@scistats
Posted 2018-05-23T13:06:20Z
$MACK If Ipsen accepts any payments for RIGHT-TO-TRY Onivyde for milestone-related indications, their profiting should trigger milestones.
@scistats
Posted 2018-05-23T12:59:25Z
$MACK RIGHT-TO-TRY LAW: Senate passed. House approved. President Trump to sign. IS ONIVYDE NOW DE FACTO FDA APPROVED FOR FRONT-LINE PC?
@stephenarmstrong
Posted 2018-05-23T12:33:33Z
$MACK Big News. Terminal patients can now try drugs that have passed phase one. Congress has passed and President to sign today.
@stephenarmstrong
Posted 2018-05-23T03:45:04Z
$MACK When was the last time anyone from management actually bought shares out of their own pocket? There's your answer.
@stephenarmstrong
Posted 2018-05-23T03:43:12Z
$MACK Oh, they'll dilute alright. That's what they excel at. It's up for shareholder vote this time. In the past, they have just done it.
@EstimizeAlerts
Posted 2018-05-23T00:40:34Z
$MACK reported -1.33 EPS and 0.00 revenue last quarter. Next report is 11/07 BMO. Jury is still out on expectations. What's yours? http://www.estimize.com/intro/mack?chart=historical&metric_name=eps&utm_content=MACK&utm_medium=report_date&utm_source=stocktwits
@TheTradTrader
Posted 2018-05-22T15:58:41Z
$MACK If date is +++ they damn well better dilute. I want this whole company to keep its good products. Not diluting would be stupid.
@SwingTradeBot
Posted 2018-05-22T14:25:42Z
Recent $MACK technical alerts: Bollinger Band Squeeze plus 6 more alerts... https://swingtradebot.com/equities/MACK
@kingscats
Posted 2018-05-22T13:58:11Z
$MACK They will dilute either right before or after news (data readout) - wait and watch!
@scistats
Posted 2018-05-22T13:48:31Z
$MACK Firewall is 450M milestones, MM121 X2 & MM310. The delay in partnerships is very interesting.
@TheTradTrader
Posted 2018-05-22T13:38:10Z
$MACK A $131 mil market cap? This is panc ca.
@TheTradTrader
Posted 2018-05-22T13:37:49Z
$MACK If 141 shows strong results a billion $ market cap is in no way unrealistic. $10/share after positive panc ca results? Keep dreaming
@TheTradTrader
Posted 2018-05-22T13:36:30Z
$MACK I think people don’t understand how this is going to work. It’s actually quite a sideshow. If 141 is strongly+++ we can hit $100
@kingscats
Posted 2018-05-22T13:34:17Z
$MACK The sad part is that even with a 50% jump in price with any news - this will be only at $13!
@scistats
Posted 2018-05-22T13:09:15Z
$MACK MM-141 is now 11 months, 4 days since enrollment completion. All patients are high serum IGF-1.
@ghostbat
Posted 2018-05-22T05:10:06Z
$MACK Night job
@ghostbat
Posted 2018-05-22T05:09:53Z
$MACK I’m not sure what’s going to happen with this one but I am sure glad that I have a day job.
MACK LATEST NEWS
Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1
Posted Wed, 09 May 2018 16:35:10 Z
Merrimack Pharmaceuticals Inc MACK reported a loss of 1 33 per share for the first quarter of 2018 which was wider than the Zacks Consensus Estimate of a loss of 1 28 The company had reported a loss of 2 20 in the year ago quarter We remind investors that Merrimack sold its sole... >>> Read More
Merrimack (MACK) Reports Wider-than-Expected Q1 Loss
Posted Tue, 08 May 2018 13:35:36 Z
Merrimack Pharmaceuticals Inc MACK is a Cambridge MA based development stage biopharmaceutical company focused on developing innovative therapies in combination with companion diagnostics for the treatment of cancer Being a development stage company Merrimack does not have any... >>> Read More
What's in the Cards for Merrimack (MACK) in Q1 Earnings?
Posted Thu, 03 May 2018 16:14:21 Z
Merrimack Pharmaceuticals Inc MACK is scheduled to report first quarter 2018 results on May 8 before market open Last quarter Merrimack beat bottom line expectations by 29 92 Merrimack s shares have declined 12 8 so far this year compared with the industry s decline of 10... >>> Read More
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
Posted Tue, 13 Mar 2018 16:13:36 Z
Merrimack Pharmaceuticals Inc MACK reported a loss of 89 cents per share in the fourth quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 1 27 The company reported a loss of 2 93 in the year ago quarter Merrimack Pharmaceuticals Inc Price and... >>> Read More
What's in the Cards for Merrimack (MACK) in Q4 Earnings?
Posted Fri, 23 Feb 2018 16:12:29 Z
Merrimack Pharmaceuticals Inc MACK is expected to report fourth quarter 2017 results on Mar 7 Last quarter Merrimack beat bottom line expectations by 78 72 Merrimack s shares have tumbled 63 3 over a year compared with the industry s decline of 2 1 Let s see how... >>> Read More

WINGCHARTS.COM    HOW IT WORKS    TRADE SIGNALS    SCREENER    MY PORTFOLIO    HELP

 



Follow Us on StockTwits
Partners / Affiliates

Copyright © 2017 WingCapital Co., Ltd. All Rights Reserved.

Disclaimer: Past results are not necessarily indicative of future performance. This website is for educational purposes only. No content published in this website, services and products constitutes a recommendation that any particular investment, security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Practical use of the content, forecasts, charts and services provided in this website are at your own risk and WingCapital Co., Ltd., WingCharts.com, its partners, representatives and employees assume no responsibility or liability for any use of the website. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Trade signals shown are hypothetical and do not represent actual trades. Actual results may differ. Views, forecasts and commentaries expressed in this website are WingCapital Co., Ltd.'s own opinions, and are not guarantees of future performance, and are subject to change over time.

WingCharts.com and WingCapital Co., Ltd. are not registered investment advisor or a broker dealer and do not give individualized market advice. The information on this website is for illustration purposes only and should not be considered as a solicitation of an offer on the purchase or sale of any securities. Trading in the securities markets involves substantial risk and should not be undertaken without due diligence and serious independent study. WingCapital Co., Ltd. recommends consulting a licensed professional broker regarding your personal investments. Without limitation, WingCapital Co., Ltd. shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscribers inability to use or any delay in accessing the WingCharts.com website or any other source of material provided by WingCharts.com and WingCapital Co., Ltd.; (3) any absence or error of material on WingCharts.com website or presentation; (4) WingCapital Co., Ltd. failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material.

ALL INFORMATION AND MATERIALS ARE PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.